JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266375

Human UBE2S knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBE2S KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.

View Alternative Names

AA409170, E2-EPF, EPF5, MGC101982, UBE2S_HUMAN, Ubiquitin carrier protein S, Ubiquitin conjugating enzyme E2 24 kD, Ubiquitin-conjugating enzyme E2 S, Ubiquitin-conjugating enzyme E2-24 kDa, Ubiquitin-conjugating enzyme E2-EPF5, Ubiquitin-protein ligase S

2 Images
Sanger Sequencing - Human UBE2S knockout HEK-293T cell line (AB266375)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2S knockout HEK-293T cell line (AB266375)

Homozygous : 1 bp deletion in exon 2

Sanger Sequencing - Human UBE2S knockout HEK-293T cell line (AB266375)
  • Sanger seq

Lab

Sanger Sequencing - Human UBE2S knockout HEK-293T cell line (AB266375)

Sequencing chromatogram displaying sequence edit in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266375-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266375 Human UBE2S knockout HEK-293T cell line", "number":"AB266375-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266375-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266375 Human UBE2S knockout HEK-293T cell line", "number":"AB266375-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBE2S
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UBE2S also known as Ubiquitin-conjugating enzyme E2 S is an important player in the ubiquitin-proteasome system. This enzyme has a mass of approximately 22 kDa. UBE2S is highly expressed in tissues with rapid proliferation such as testes and certain types of tumors. Its main function involves catalyzing the elongation of ubiquitin chains specifically on lysine 11 a modification that predominantly signals for cell cycle-related proteolysis.
Biological function summary

UBE2S acts within the anaphase-promoting complex/cyclosome (APC/C) an important multi-subunit E3 ubiquitin ligase. Through its activity UBE2S facilitates the progression of the mitotic cycle by tagging key regulatory proteins for degradation aiding in their timely removal during cell division. Without this regulation cells struggle with correct chromosomal segregation which can lead to genomic instability.

Pathways

UBE2S functions notably within the cell cycle regulation and protein degradation pathways. It collaborates closely with the anaphase-promoting complex/cyclosome (APC/C) and cooperates with related proteins such as CDC20 and CDH1. By enabling the degradation of securin and cyclins UBE2S helps manage the transition from metaphase to anaphase ensuring cells divide properly in mitotic processes.

UBE2S has strong implications in cancer development particularly in breast and lung cancers. Overexpression of UBE2S often correlates with tumor progression and poor prognosis due to its role in promoting uncontrolled cell division. Additionally linkages between UBE2S and proteins like cyclin B1 suggest disruptions might contribute to tumor cell survival providing potential therapeutic targets in oncology.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com